Synovial Fibroblast 3.2: Secretion response of seven primary human synovial fibroblast samples from healthy and rheumatoid arthritis-diagnosed donors to a panel of 3 stimuli and 5 small molecule inhibitors (replicate 2 of 2) - Dataset (ID:20235)
- Detail
- Small Molecules Studied
- Primary Cells Studied
- Proteins Studied
- Unclassified Perturbagens Studied
- Data Columns
- Results
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | Protein Stimulus | Other Stimulus | Stimulus Concentration | Stimulus Conc Unit | ExpPlate | Measured Protein | Measured Protein MFI (a.u.) | Bead Count |
---|---|---|---|---|---|---|---|---|---|---|---|
RA2159 | 5z-7-oxozeaenol | 0.6 | uM | Poly(I:C) | 2 | ug/mL | 4 | IP-10 | 325.5 | 40 | |
RA2159 | IKK16 | 2.0 | uM | Poly(I:C) | 2 | ug/mL | 4 | IP-10 | 855.0 | 63 | |
N2645 | 5z-7-oxozeaenol | 0.6 | uM | Poly(I:C) | 2 | ug/mL | 4 | IP-10 | 32.0 | 57 | |
N2645 | IKK16 | 2.0 | uM | Poly(I:C) | 2 | ug/mL | 4 | IP-10 | 109.5 | 64 | |
RA2708 | 5z-7-oxozeaenol | 0.6 | uM | Poly(I:C) | 2 | ug/mL | 4 | IP-10 | 222.0 | 52 | |
RA2708 | IKK16 | 2.0 | uM | Poly(I:C) | 2 | ug/mL | 4 | IP-10 | 140.0 | 59 | |
RA2159 | Tofacitinib | 0.3 | uM | Poly(I:C) | 2 | ug/mL | 4 | IP-10 | 3008.0 | 55 | |
RA2159 | Poly(I:C) | 2 | ug/mL | 4 | IP-10 | 6634.5 | 46 | ||||
N2645 | Tofacitinib | 0.3 | uM | Poly(I:C) | 2 | ug/mL | 4 | IP-10 | 2813.0 | 49 | |
N2645 | Poly(I:C) | 2 | ug/mL | 4 | IP-10 | 16104.0 | 54 | ||||
RA2708 | Tofacitinib | 0.3 | uM | Poly(I:C) | 2 | ug/mL | 4 | IP-10 | 7789.0 | 33 | |
RA2708 | Poly(I:C) | 2 | ug/mL | 4 | IP-10 | 6401.5 | 54 | ||||
RA2159 | 5z-7-oxozeaenol | 0.6 | uM | IL-1 alpha | 100 | ng/mL | 4 | IP-10 | 21.0 | 62 | |
RA2159 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 4 | IP-10 | 22.0 | 57 | |
N2645 | 5z-7-oxozeaenol | 0.6 | uM | IL-1 alpha | 100 | ng/mL | 4 | IP-10 | 19.0 | 54 | |
N2645 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 4 | IP-10 | 32.0 | 50 | |
RA2708 | 5z-7-oxozeaenol | 0.6 | uM | IL-1 alpha | 100 | ng/mL | 4 | IP-10 | 17.0 | 57 | |
RA2708 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 4 | IP-10 | 23.0 | 49 | |
RA2159 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 4 | IP-10 | 123.0 | 59 | |
RA2159 | IL-1 alpha | 100 | ng/mL | 4 | IP-10 | 161.0 | 57 | ||||
N2645 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 4 | IP-10 | 427.5 | 52 | |
N2645 | IL-1 alpha | 100 | ng/mL | 4 | IP-10 | 725.0 | 72 | ||||
RA2708 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 4 | IP-10 | 552.0 | 50 | |
RA2708 | IL-1 alpha | 100 | ng/mL | 4 | IP-10 | 1034.5 | 48 | ||||
RA2159 | 5z-7-oxozeaenol | 0.6 | uM | TNF-a | 100 | ng/mL | 4 | IP-10 | 53.0 | 45 |